Core Viewpoint - WuXi AppTec Co., Ltd. is expected to achieve significant growth in its 2025 financial performance, driven by its integrated CRDMO business model and strategic focus on enhancing production capabilities and operational efficiency [2][9]. Financial Performance Forecast - The company anticipates a revenue of approximately RMB 45.46 billion for 2025, representing a year-on-year increase of about 15.84%, with revenue from continuing operations expected to grow by approximately 21.40% [5][6]. - Adjusted net profit attributable to shareholders is projected to be around RMB 14.96 billion, reflecting a year-on-year growth of approximately 41.33% [6]. - The net profit attributable to shareholders, excluding non-recurring gains and losses, is expected to be about RMB 13.24 billion, with a year-on-year increase of approximately 32.56% [6]. - The total net profit attributable to shareholders is forecasted to be around RMB 19.15 billion, showing a substantial year-on-year growth of approximately 102.65%, which includes gains from the sale of equity interests and divestitures [3][6]. - The basic earnings per share are expected to be approximately RMB 6.70, marking a year-on-year increase of about 104.27% [3][6]. Business Model and Growth Drivers - The company continues to focus on its unique "integrated, end-to-end" CRDMO business model, addressing customer needs for empowerment and expanding new capabilities while optimizing production processes [2][9]. - The growth in revenue and profit is attributed to the company's commitment to delivering new and effective drugs to global patients [9]. Non-Operating Gains - Non-operating gains are expected to significantly impact net profit, primarily from the sale of a portion of equity in WuXi XDC Cayman Inc., estimated at approximately RMB 416.09 million, and the sale of 100% equity in two other companies, expected to yield around RMB 143.38 million [10].

剑桥科技(06166)控股子公司通过高新技术企业认定 智谱(02513)回应与出行平台合作不涉内幕消息 业务推进属日常范畴 重大事项： 红星冷链(01641)：香港公开发售获2309.25倍认购 每股发售价12.26港元 BBSB INTL(08610)：公开发售获10745.13倍认购 每股发售价0.6港元 兆易创新(03986)香港公开发售获542.22倍认购 全球发售净筹约46.11亿港元 恒瑞医药(01276)：注射用SHR-1826被药审中心纳入突破性治疗品种名单 百奥赛图-B(02315)通过基于选择权的评估框架与育世博达成进一步合作共同推进同类首创双特异性抗 体双药物偶联物项目 东风集团股份(00489)2025年度累计汽车销量为189.62万辆 同比增长约0.01% 中银航空租赁(02588)2025年全年自有飞机利用率保持在100% 龙湖集团(00960)2025年度累计实现总合同销售金额631.6亿元 中国软件国际(00354)投资企业MiniMax(00100)港交所上市 全栈AI战略版图再拓新篇 达力普控股(01921)拟300万沙特里亚尔出售达力普国际40%股权 引入沙特战略投资者推 ...

Core Viewpoint - WuXi AppTec (603259.SH) has released an earnings forecast for 2025 that exceeds its previously raised guidance, indicating strong revenue and net profit growth driven by its integrated CRDMO model and non-recurring gains from asset disposals [1] Group 1: Financial Performance - The company expects to achieve a total revenue of 45.456 billion yuan in 2025, representing a year-on-year increase of 15.84%, with core business revenue growing approximately 21.40% [1] - Adjusted net profit attributable to shareholders is projected to be 14.957 billion yuan, reflecting a year-on-year growth of about 41.33%, while net profit attributable to the company’s shareholders is expected to reach 19.151 billion yuan, marking a significant increase of approximately 102.65% [1] - The company has raised its annual revenue guidance for the second time within a year, adjusting the expected range from 42.5-43.5 billion yuan to 43.5-44 billion yuan [1] Group 2: Business Segments - The TIDES business (oligonucleotides and peptide drugs) has shown remarkable performance, with revenue reaching 7.84 billion yuan in the first three quarters, a year-on-year increase of 121.1%, setting historical highs for both the first three quarters and the third quarter [2] - Non-recurring gains from asset disposals have significantly contributed to the earnings exceeding expectations, with net gains from the sale of certain equity stakes totaling 5.595 billion yuan, accounting for 37.41% of the expected annual net profit [2] Group 3: Strategic Focus - The company is focusing on its core CRDMO areas by divesting from clinical research services, which has resulted in a gain of 1.434 billion yuan from the sale of related businesses [2] - WuXi AppTec is expanding its global footprint with ongoing construction of overseas bases in Singapore and Delaware, aiming to mitigate geopolitical risks and better meet customer demands [3] - Revenue from U.S. clients has reached 22.15 billion yuan in the first three quarters of 2025, reflecting a year-on-year growth of 31.9% and increasing its share of total revenue to 67%, becoming a key growth driver [3]

今日焦点 华是科技：控股股东、实际控制人等筹划控制权变更事项，股票停牌 华是科技公告称，公司控股股东、实际控制人俞永方、叶建标和持股5%以上股东章忠灿正在筹划重大 事项，可能导致公司控制权发生变动。为保证公平信息披露，维护投资者利益，避免造成公司股价异常 波动，公司股票自2026年1月13日开市起停牌，预计停牌时间不超过2个交易日。停牌期间，公司将根据 事项进展情况，严格按照法律法规的规定和要求履行信息披露义务。待上述事项确定后，公司将及时披 露相关公告并申请公司股票复牌。 卓易信息发布异动公告，公司IDE业务在2024及2025年陆续发布了两款AI编程产品，尚处于市场导入 期，在初步商业化阶段，产品技术路径、编程效果及市场接受度存在不确定性，目前尚未形成规模化的 产品体系，技术迭代及商业化进展可能不及预期。目前两款产品使用用户以免费用户为主，尚未形成稳 定、可持续的收入来源。未来产品的收入规模、盈利水平及现金流贡献存在高度不确定性，短期内对公 司整体经营业绩影响有限。DeepSeek、通义千问等均系开源大语言模型，任何用户皆可免费基于该模 型开展训练工作，进而进行个性化开发或模型优化，以满足不同用户在多元场 ...

Core Viewpoint - WuXi AppTec expects to achieve a revenue of approximately RMB 4,545,617 million in 2025, representing a year-on-year growth of about 15.84% [1] - The revenue from continuing operations is projected to grow by approximately 21.40% year-on-year [1] - The company anticipates a net profit attributable to shareholders of approximately RMB 1,915,058 million, reflecting a year-on-year increase of about 102.65% [1] Summary by Category - **Revenue Projections** - Expected revenue for 2025 is approximately RMB 4,545,617 million, with a growth rate of 15.84% compared to the previous year [1] - Revenue from continuing operations is projected to grow by 21.40% year-on-year [1] - **Net Profit Expectations** - Anticipated net profit for shareholders is around RMB 1,915,058 million, indicating a significant increase of 102.65% year-on-year [1]

Core Viewpoint - WuXi AppTec has raised its revenue forecast for 2025 for the third time, indicating strong growth potential in its business operations [1] Group 1: Revenue Forecast - The company expects to achieve approximately 45.456 billion yuan in revenue for 2025, representing a year-on-year growth of about 15.84% [1] - Revenue from continuing operations is projected to grow by approximately 21.40% year-on-year [1] - The previous revenue forecast was adjusted from a range of 42.5 billion to 43.5 billion yuan to a new range of 43.5 billion to 44 billion yuan [1] Group 2: Profitability - The company anticipates a net profit attributable to shareholders of approximately 19.151 billion yuan for 2025, reflecting a year-on-year increase of about 102.65% [1] - This net profit is expected to set a new historical high for the company [1]

Core Viewpoint - WuXi AppTec (603259.SH, 02359.HK) has raised its revenue forecast for 2025 for the third time, expecting approximately 45.456 billion yuan in revenue, a year-on-year increase of about 15.84%, with a significant net profit forecast of around 19.151 billion yuan, representing a 102.65% increase year-on-year, marking a historical high for the company [1][3]. Group 1 - The company expects 2025 revenue to reach approximately 45.456 billion yuan, with a year-on-year growth of about 15.84%, and a 21.40% increase in revenue from continuing operations [1]. - The previous revenue forecast was adjusted from 42.5-43.5 billion yuan to 43.5-44 billion yuan during the Q3 report [1]. - The anticipated net profit for 2025 is approximately 19.151 billion yuan, which is a historical high and represents a year-on-year increase of about 102.65% [1][3]. Group 2 - The company focuses on a unique "integrated, end-to-end" CRDMO (Contract Research, Development, and Manufacturing) business model, enhancing production efficiency and expanding capabilities to drive steady business growth [3]. - Significant net profit contributions are expected from the sale of assets, including approximately 4.161 billion yuan from the sale of shares in WuXi AppTec's subsidiary and about 1.434 billion yuan from the sale of 100% equity in two clinical research companies, totaling nearly 5.6 billion yuan in net gains [3]. - The asset sales align with the company's strategy to focus on the CRDMO business model, providing funding support for global capacity expansion [3].

Core Viewpoint - WuXi AppTec (药明康德) anticipates an increase in revenue and net profit for the fiscal year ending December 31, 2025, compared to the same period in 2024, driven by its integrated CRDMO business model and strategic asset sales [1][2]. Group 1: Financial Performance - The company expects to achieve revenue of approximately RMB 45,456.17 million, representing a year-on-year growth of about 15.84%, with a 21.40% increase in revenue from continuing operations [1]. - Adjusted net profit attributable to shareholders is projected to be around RMB 14.957 billion, reflecting a year-on-year growth of approximately 41.33% [1]. - The net profit attributable to shareholders, excluding non-recurring gains and losses, is expected to be about RMB 13.241 billion, with a year-on-year increase of approximately 32.56% [1]. - The total net profit attributable to shareholders is anticipated to be around RMB 19.151 billion, showing a significant year-on-year growth of approximately 102.65% [1]. - Basic earnings per share are expected to be approximately RMB 6.70, representing a year-on-year increase of about 104.27% [1]. Group 2: Business Strategy and Operations - The company continues to focus on its unique "integrated, end-to-end" CRDMO business model, enhancing capabilities and building new production capacity to meet customer demands [2]. - The impact of non-recurring gains on net profit primarily stems from the sale of a portion of its stake in WuXi XDC Cayman Inc., expected to yield a net gain of approximately RMB 4.161 billion, and the sale of 100% stakes in Shanghai Kangde Hongyi Medical Clinical Research Co., Ltd. and Shanghai WuXi Jinshi Pharmaceutical Technology Co., Ltd., expected to yield a net gain of approximately RMB 1.434 billion [2].

Core Viewpoint - WuXi AppTec is expected to achieve significant revenue and profit growth in 2025, driven by its core business operations and strategic asset sales [1] Financial Performance - The company anticipates total revenue of approximately RMB 45.46 billion for 2025, representing a year-on-year increase of about 15.8% [1] - Revenue from continuing operations is projected to grow by approximately 21.4% year-on-year [1] - The expected net profit attributable to shareholders is around RMB 19.15 billion, reflecting a substantial year-on-year growth of approximately 102.6% [1] - The basic earnings per share for 2025 is estimated to be about RMB 6.70, which indicates a year-on-year increase of approximately 104.3% [1]

智通财经APP获悉，1月12日晚间，药明康德(603259.SH/02359)披露了其2025年度预增公告。公告显示，公司预计全年营业收入约456.56亿元，同比增长约 15.84%；其中持续经营业务收入同比增长约21.4%。盈利方面，经调整non-IFRS归母净利润、归母净利润、扣非归母净利润分别同比增长约41.33%、 102.65%及32.56%，基本每股收益同样翻倍达到6.7元。 在归母净利润、每股收益达成新高的背景下，药明康德2025年度现金分红亦有望创下新高。按照此前，公司在三季度业绩交流会上曾表示，上市以来一贯维 持约30%的现金分红比例。根据本次预告的归母净利润测算，2025年度现金分红总额预计将突破57亿元。 根据统计，上市以来的七年时间里，药明康德通过现金分红、回购及注销股份的方式，累计回馈投资者达到200亿元，超过了公司过去七年累计净利润的 40%。 ...